149 related articles for article (PubMed ID: 18093475)
1. [Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck].
Al Kassam D; Alvarez Marcos C; Blanco I; de Los Toyos JR; Llorente JL
Med Clin (Barc); 2007 Dec; 129(20):761-5. PubMed ID: 18093475
[TBL] [Abstract][Full Text] [Related]
2. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
[TBL] [Abstract][Full Text] [Related]
3. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract.
Wang WL; Chang WL; Yeh YC; Lee CT; Chang CY; Lin JT; Sheu BS
Mol Carcinog; 2013 Jun; 52(6):438-45. PubMed ID: 22241750
[TBL] [Abstract][Full Text] [Related]
4. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
5. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma.
Chow V; Yuen AP; Lam KY; Ho WK; Wei WI
Head Neck; 2001 Apr; 23(4):286-91. PubMed ID: 11400229
[TBL] [Abstract][Full Text] [Related]
8. Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis.
Kawata R; Shimada T; Maruyama S; Hisa Y; Takenaka H; Murakami Y
Acta Otolaryngol; 2002 Jan; 122(1):101-6. PubMed ID: 11876588
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Int J Cancer; 2005 Sep; 116(3):422-7. PubMed ID: 15818624
[TBL] [Abstract][Full Text] [Related]
10. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of head and neck tumor markers].
Gascón Vilaplana P
Med Clin (Barc); 2007 Dec; 129(20):775-6. PubMed ID: 18093479
[No Abstract] [Full Text] [Related]
12. Serum levels of intercellular adhesion molecule-1 in squamous cell carcinoma of the head and neck.
Wollenberg B; Jan N; Sautier W; Hofmann K; Schmitt UM; Stieber P
Tumour Biol; 1997; 18(2):88-94. PubMed ID: 9222306
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinase-12 is correlated with extracapsular spread of tumor from nodes with metastasis in head and neck squamous cell carcinoma.
Kim JM; Kim HJ; Koo BS; Rha KS; Yoon YH
Eur Arch Otorhinolaryngol; 2013 Mar; 270(3):1137-42. PubMed ID: 22907031
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.
Colnot DR; Nieuwenhuis EJ; Kuik DJ; Leemans CR; Dijkstra J; Snow GB; van Dongen GA; Brakenhoff RH
Clin Cancer Res; 2004 Dec; 10(23):7827-33. PubMed ID: 15585614
[TBL] [Abstract][Full Text] [Related]
15. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.
Ranuncolo SM; Matos E; Loria D; Vilensky M; Rojo R; Bal de Kier Joffé E; Inés Puricelli L
Cancer; 2002 Mar; 94(5):1483-91. PubMed ID: 11920505
[TBL] [Abstract][Full Text] [Related]
16. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
Do NY; Lim SC; Im TS
Oncol Rep; 2004 Aug; 12(2):229-37. PubMed ID: 15254682
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of microvessel density and p53 expression on the locoregional metastasis and survival of the patients with head and neck squamous cell carcinoma.
de Oliveira MV; Pereira Gomes EP; Pereira CS; de Souza LR; Barros LO; Mendes DC; Guimarães AL; De Paula AM
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):444-51. PubMed ID: 23343952
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
[TBL] [Abstract][Full Text] [Related]
20. Markers for nodal metastasis in head and neck squamous cell cancer.
Takes RP; Baatenburg De Jong RJ; Alles MJ; Meeuwis CA; Marres HA; Knegt PP; De La Riviere GB; De Wilde PC; Mooi WJ; Hermans J; Van Krieken JH
Arch Otolaryngol Head Neck Surg; 2002 May; 128(5):512-8. PubMed ID: 12003581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
